Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

William Raoofi

Pain Medicine Baltimore, MD Medical Doctor

NPI 1467846063 CMS profile 7226842

345 Saint Paul St, Baltimore, MD 21202

Open in the dashboard

General payments

$4,808

66 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, William Raoofi of Baltimore, MD is reported in the CMS Open Payments database as having received $4,808 across 66 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 72nd percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $376 7
2024 General $224 5
2023 General $342 12
2022 General $1,444 18
2021 General $261 8
2020 General $78 2
2019 General $2,084 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Raoofi
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to William Raoofi were reported at $376. Among 1,144 Pain Medicine profiles paid that year, the median was $402 and the middle half received between $130 and $1,173.

Show as a table
Year William Raoofi Pain Medicine median Middle half National median
2019 $2,084 $409 $115–$1,311 $163
2020 $78 $214 $66–$666 $114
2021 $261 $299 $84–$899 $132
2022 $1,444 $335 $103–$1,149 $149
2023 $342 $376 $114–$1,228 $160
2024 $224 $387 $115–$1,173 $164
2025 $376 $402 $130–$1,173 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $1,433 13 payments
  2. Spinal Simplicity, LLC $1,003 8 payments
  3. Medtronic USA, Inc. $828 7 payments
  4. Nevro Corp. $689 14 payments
  5. Globus Medical, Inc. $353 6 payments
  6. Abbott Laboratories $222 8 payments
  7. Vertos Medical, Inc. $111 1 payment
  8. Averitas Pharma Inc. $45 2 payments
  9. Relievant Medsystems, Inc. $40 2 payments
  10. IBSA Pharma Inc. $33 2 payments
  11. Other $51 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $2,457 11 payments
  2. Food and Beverage $2,351 55 payments
Products named General payments · program years 2019–2025
  1. SPECTRA WAVEWRITER $1,146 4 payments
  2. HA MINUTEMAN G3-R $1,003 8 payments
  3. RESTORE $644 5 payments
  4. Omnia $469 8 payments
  5. Senza Spinal Cord Stimulator $353 6 payments
  6. Senza Spinal Cord Stimulator $220 6 payments
  7. INTELLIS $184 2 payments
  8. WaveWriter Alpha Prime 16 $136 4 payments
  9. mild Device Kit $111 1 payment
  10. GENERAL PAIN MANAGEMENT $110 3 payments
  11. Other $525 23 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

702

Median for Pain Management: 951

Drug cost

$9,059

Median for Pain Management: $26,034

Branded share of claims

0%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 147 $2,847
Pregabalin Generic 77 $1,626
Celecoxib Generic 46 $1,159
Tizanidine Hcl Generic 104 $1,128
Meloxicam Generic 112 $510
Methylprednisolone Generic 58 $409
Baclofen Generic 12 $363
Duloxetine Hcl Generic 12 $243
Diclofenac Sodium Generic 20 $237
Tramadol Hcl Generic 70 $234

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 50 billing codes

Paid by Medicare

$170,659

Of which drugs: $60

Medicare patients

627

Average age 74

Services billed

1,980

408 women, 219 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 30%
Diabetes 29%
Ischemic heart disease 26%
Osteoporosis 20%
Chronic kidney disease 19%
Cancer 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

66 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record